Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

According to the abstract, 219 patients were involved.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

Osteoporotic 219 patients were randomly assigned to the ALN + ELD, or the ALN + VitD group.

Primary endpoint was the inter-group differences in lumbar spine BMD (L-BMD) at patient's last visit.

How the Study Was Run

The design is described as randomized.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Secondary endpoints included the differences in BMD at other sites and the bone turnover marker (BTM) levels.

What Was Measured

The subject headings attached to it are Alendronate, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Calcium and Cholecalciferol.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 219 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.